Drugs / Pembrolizumab
Drug research

Pembrolizumab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as KEYTRUDA®; Keytruda

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)NCT05155254IO BiotechPhase 3Active not recruiting2025-05-30Actual
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCNCT06216301NovoCure GmbHPhase 3Recruiting2028-10Estimated
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332IDEAYA BiosciencesPhase 2, Phase 3Active not recruiting2027-01-15Estimated
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]NCT06264180Replimune, Inc.Phase 3Recruiting2030-09-30Estimated
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)NCT07660094CADLPhase 3Recruiting2031-10-22Estimated
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCNCT06246110Eikon TherapeuticsPhase 2Active not recruiting2026-12Estimated
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerNCT03520686IBRXPhase 3Terminated2025-10-13Actual
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS MutationsNCT04854434KPTIPhase 2Terminated2022-06-24Actual
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckNCT05271604BioAtla, Inc.Phase 2Completed2025-09-22Actual
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNCT04736173RCUSPhase 2Active not recruiting2027-05Estimated
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaNCT03070392Immunocore LtdPhase 2Completed2020-10-13Actual
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928IOVAPhase 2Terminated2026-02-20Actual
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCCNCT06295731INBXPhase 2, Phase 3Active not recruiting2029-05Estimated
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer PatientsNCT02826486BLRXPhase 2Completed2022-09-06Actual
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced MelanomaNCT04768881KPTIPhase 2Terminated2023-09-22Actual
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaNCT06556563NovoCure GmbHPhase 3Recruiting2029-04Estimated
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06082167ExelixisPhase 2, Phase 3Active not recruiting2028-08Estimated
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerNCT06282575Jazz PharmaceuticalsPhase 3Recruiting2028-12-01Estimated
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)NCT06558799NovoCure GmbHPhase 2Terminated2026-02-23Actual

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.